期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Amphiphilic sodium alginate-vinyl acetate microparticles for drug delivery 被引量:3
1
作者 YU Weiting ZHANG Demeng +4 位作者 LIU Xiudong WANG Yunhong TONG Jun ZHANG Mengxue MA Xiaojun 《Journal of Oceanology and Limnology》 SCIE CAS CSCD 2019年第3期855-862,共8页
To overcome the fast or burst release of hydrophilic drugs from hydrophilic alginate-based carriers,hydrophobic molecule(vinyl acetate,VAc)was grafted on alginate(Alg),which was further used to prepare drug carriers.A... To overcome the fast or burst release of hydrophilic drugs from hydrophilic alginate-based carriers,hydrophobic molecule(vinyl acetate,VAc)was grafted on alginate(Alg),which was further used to prepare drug carriers.Amphiphilic Alg-g-PVAc hydrogel beads were firstly prepared by emulsification/internal gelation technique for the loading of bovine serum albumin(BSA).Then,chitosan was coated on the surface of beads to form novel amphiphilic Alg-g-PVAc/chitosan(Alg-g-PVAc/CS)microcapsules.The BSA-loading amphiphilic Alg-g-PVAc/chitosan(Alg-g-PVAc/CS)microcapsules display similar morphology and size to the hydrophilic alginate/chitosan(AC)microcapsules.However,the drug loading and loading efficiency of BSA in Alg-g-PVAc/CS microcapsules are higher,and the release rate of BSA from Alg-g-PVAc/CS microcapsules is slower.The results demonstrate that the introduction of hydrophobic PVAc on alginate can effectively help retard the release of BSA,and the higher degree of substitution is,the slower the release rate is.In addition,the complex membrane can also be adjusted to delay the release of BSA.As a whole,amphiphilic sodium alginate-vinyl acetate/CS microparticles could be developed for macromolecular drug delivery. 展开更多
关键词 hydrophobic modifi cation sodium alginate-vinyl ACETATE amphiphilic Alg-g-PVAc/chitosan MICROCAPSULES drug delivery
下载PDF
药物诱导磷脂沉积症的安全性问题和风险控制策略
2
作者 余珊珊 尹华静 +4 位作者 王寅 吴爽 李铮 尹茂山 胡晓敏 《中国新药杂志》 CAS CSCD 北大核心 2018年第18期2131-2136,共6页
药物诱导磷脂沉积症(PLD)是指药物和磷脂在细胞溶酶体中过度沉积的现象。不同结构的阳离子两亲性药物可通过不同的作用机制诱导PLD。部分小分子化合物在诱导PLD的同时,还导致靶组织器官毒性和功能损伤。在审评实践中,当缺少足够证据排除... 药物诱导磷脂沉积症(PLD)是指药物和磷脂在细胞溶酶体中过度沉积的现象。不同结构的阳离子两亲性药物可通过不同的作用机制诱导PLD。部分小分子化合物在诱导PLD的同时,还导致靶组织器官毒性和功能损伤。在审评实践中,当缺少足够证据排除PLD相关临床安全性风险时,监管机构倾向于认为药物诱导PLD是给药相关的不良反应。随着对PLD安全性风险的深入理解,制定科学筛选和临床风险防控措施可以更好地指导新药研发中的候选化合物选择,并增加监管机构批准候选化合物进入临床试验的信心。本文综述了PLD的机制、相关非临床安全性风险以及分级风险防控策略,对审评案例进行了讨论,供业内参考。 展开更多
关键词 药物诱导磷脂沉积症 阳离子两亲性药物 风险控制策略
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部